Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - etoricoxib - film coated tablet - 120 milligram - coxibs

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - etoricoxib - film coated tablet - 90 milligram - coxibs

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - etoricoxib - oral tablet - 60mg

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 120mg; etoricoxib 120mg - film coated tablet - 120 mg - active: etoricoxib 120mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water active: etoricoxib 120mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 60mg; etoricoxib 60mg - film coated tablet - 60 mg - active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 90mg; etoricoxib 90mg - film coated tablet - 90 mg - active: etoricoxib 90mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water active: etoricoxib 90mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - etoricoxib - oral tablet - 60mg

Kenya - English - Pharmacy and Poisons Board

etoricoxib, paracetamol - tablet - etoricoxib 60 mg, paracetamol 500 mg - etoricoxib

Ireland - English - HPRA (Health Products Regulatory Authority)

jed pharma ltd - paracetamol; ibuprofen sodium dihydrate - solution for infusion - 10/3 milligram(s)/millilitre - paracetamol, combinations excl. psycholeptics

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.